177Lu radiolabeled peptides for breast cancer therapy [abstract]

MOspace/Manakin Repository

Breadcrumbs Navigation

177Lu radiolabeled peptides for breast cancer therapy [abstract]

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/9144

[-] show simple item record

dc.contributor.advisor Quinn, Thomas P. (Thomas Patrick), 1961- en_US
dc.contributor.author Calzada, Victoria
dc.contributor.author Zhang, Xiuli
dc.contributor.author Cabral, Pablo
dc.contributor.author Fernandez, Marcelo
dc.contributor.author Gambini, Juan Pablo
dc.date.accessioned 2010-12-03T15:48:30Z
dc.date.available 2010-12-03T15:48:30Z
dc.date.issued 2010-11-11
dc.identifier.uri http://hdl.handle.net/10355/9144
dc.description.abstract ErbB-2 is a type 1 receptor tyrosine kinase over-expressed on ~30% of breast cancers and is an attractive target for the development of new diagnostic and therapeutic agents. The ErbB-2 avid peptide KCCYSL, originally identified from phage display, has shown promising imaging results in pre-clincial breast carcinoma animal models. In this study the peptide DOTA-GSGKCCYSL was radiolabeled with the beta-particle emitter lutetium-177 (177Lu) and examined for its therapeutic potential. The peptide DOTA-GSG-KCCYSL was synthesized using Fmoc solid phase peptide synthesis and purified to homogeneity. DOTA-GSG-KCCYSL was radiolabeled with Lu-177 and purified via high performance liquid chromatography. In vitro stability studies showed that the radiolabeled complex was stable to challenges from metal chelators and was stable to >60% in serum at 37˚C over 24 h. Cell binding of 177Lu-DOTA-GSG-KCCYSL to MB- 435 human breast carcinoma cells displayed saturable binding at 2 h. Log P studies indicated that the radiolabeled complex was very hydrophilic. Initial biodistribution studies in MB-435 xenografted mice showed modest tumor uptake of 1.82 % injected dose per gram (ID/g) 30 min post injection and 0.56 % ID/g at 1 h post injection. Additional biodistribution and imaging studies are underway to determine dosimetry and potential tumor therapeutic properties. en_US
dc.language.iso en_US en_US
dc.relation.ispartof 2010 Health Sciences Research Day (MU) en_US
dc.subject cancer treatment en_US
dc.subject molecular characteristics en_US
dc.title 177Lu radiolabeled peptides for breast cancer therapy [abstract] en_US
dc.type Other en_US
dc.relation.ispartofcommunity University of Missouri-Columbia. Health Sciences Research Day.


This item appears in the following Collection(s)

[-] show simple item record